Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials

被引：3

作者：

Sachanas, Sotirios ^{[1
]}

Pangalis, Gerassimos A. ^{[1
]}

Fink, Anna-Maria ^{[2
,3
]}

Bahlo, Jasmin ^{[2
,3
]}

Fischer, Kirsten ^{[2
,3
]}

Levidou, Georgia ^{[3
,4
,5
]}

Kyrtsonis, Marie-Christine ^{[6
]}

Bartzi, Vassiliki ^{[7
]}

Vassilakopoulos, Theodoros P. ^{[8
]}

Kalpadakis, Christina ^{[9
]}

Koulieris, Efstathios ^{[1
]}

Moschogiannis, Maria ^{[1
]}

Yiakoumis, Xanthi ^{[1
]}

Tsirkinidis, Pantelis ^{[1
]}

Angelopoulou, Maria K. ^{[8
]}

Eichhorst, Barbara ^{[2
,3
]}

Hallek, Michael ^{[2
,3
]}

机构：

[1] Athens Med Ctr, Psychikon Branch, Dept Haematol, 1 Andersen Str, Athens 11525, Greece

[2] Univ Hosp Cologne, German CLL Study Grp, Dept Internal Med 1, Cologne, Germany

[3] Univ Hosp Cologne, German CLL Study Grp, Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

[4] Univ Athens, Pathol Dept, Athens, Greece

[5] Humanpathol GmbH, Pathol Dept, Erlangen, Germany

[6] Univ Athens, Laikon Gen Hosp, Dept Propedeut 1, Athens, Greece

[7] Gen Hosp Karditsa, Dept Haematol, Kardhitsa, Greece

[8] Univ Athens, Laikon Gen Hosp, Dept Haematol, Athens, Greece

[9] Univ Crete, Univ Hosp, Dept Haematol, Iraklion, Greece

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 05期

关键词：

Small lymphocytic lymphoma; treatment; proliferation centers; PROLIFERATION CENTERS; CYCLOPHOSPHAMIDE; CLASSIFICATION; FLUDARABINE; RITUXIMAB;

D O I：

10.21873/anticanres.13382

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Only few studies have focused exclusively on patients with small lymphocytic lymphoma (SLL). Patients and Methods: In the present report, 103 SLL patients were analyzed from both, clinical trials of the German Chronic Lymphocytic Leukemia Study Group and Greek centers, and emphasis was placed on the therapeutic strategy. The impact of lymph node characteristics, such as the presence of proliferation centers (PCs) on response and survival was also assessed. Results: SLL patients included in clinical trials were treated mostly with fludarabine-based regimens while those in "reallife" were staged and treated mostly as patients with low-grade lymphomas. Our analysis showed a trend for better survival for patients with SLL without detectable PCs. Conclusion: Patients with SLL outside of clinical trials are usually treated as cases of lymphoma. In addition, this analysis supports published data regarding the adverse prognostic value of the presence of PCs in lymphoid nodes in SLL.

引用

页码：2591 / 2598

页数：8

共 50 条

[21] Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study
Rogers, Kerry A.
Lu, Xiaoxiao
Emond, Bruno
Cote-Sergent, Aurelie
Kinkead, Frederic
Lafeuille, Marie-Helene
Lefebvre, Patrick
Huang, Qing
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (09): : 1033 - 1045
[22] Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials
Wojdacz, Tomasz K.
Amarasinghe, Harindra E.
Kadalayil, Latha
Beattie, Alice
Forster, Jade
Blakemore, Stuart J.
Parker, Helen
Bryant, Dean
Larrayoz, Marta
Clifford, Ruth
Robbe, Pauline
Davis, Zadie A.
Else, Monica
Howard, Dena R.
Stamatopoulos, Basile
Steele, Andrew J.
Rosenquist, Richard
Collins, Andrew
Pettitt, Andrew R.
Hillmen, Peter
Plass, Christoph
Schuh, Anna
Catovsky, Daniel
Oscier, David G.
Rose-Zerilli, Matthew J. J.
Oakes, Christopher C.
Strefford, Jonathan C.
BLOOD ADVANCES, 2019, 3 (16) : 2474 - 2481
[23] INFLUENCE OF DIFFERENT TREATMENT REGIMENS ON SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - A META-ANALYSIS OF THE GERMAN CLL STUDY GROUP (GCLLSG)
Isfort, S.
Cramer, P.
Bahlo, J.
Busch, R.
Fischer, K.
Fink, A. M.
Goede, V.
Elter, T.
Bergmann, M.
Stauch, M.
Stilgenbauer, S.
Wendtner, C. M.
Hallek, M.
Eichhorst, B.
HAEMATOLOGICA, 2012, 97 : 56 - 56
[24] Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
Herishanu, Yair
Shaulov, Adir
Fineman, Riva
Basic-Kinda, Sandra
Aviv, Ariel
Wasik-Szczepanek, Ewa
Jaksic, Ozren
Zdrenghea, Mihnea
Greenbaum, Uri
Mandac, Inga
Simkovic, Martin
Morawska, Marta
Benjamini, Ohad
Spacek, Martin
Nemets, Anatoly
Bairey, Osnat
Trentin, Livio
Ruchlemer, Rosa
Laurenti, Luca
Ciocan, Oana Stanca
Doubek, Michael
Shvidel, Lev
Dali, Nagib
Miras, Fatima
De Meuter, Anne
Dimou, Maria
Mauro, Francesca R.
Coscia, Marta
Bumbea, Horia
Szasz, Robert
Tadmor, Tamar
Gutwein, Odit
Gentile, Massimo
Scarf, Lydia
Tedeschi, Alessandra
Sportoletti, Paolo
Gimeno Vazquez, Eva
Marquet, Juan
Assouline, Sarit
Papaioannou, Maria
Braester, Andrei
Levato, Luciano
Gregor, Michael
Rigolin, Gian M.
Loscertales, Javier
Medina Perez, Angeles
Nijziel, Marten R.
Popov, Viola M.
Collado, Rosa
Slavutsky, Irma
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) : 604 - 611
[25] Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials
O'Brien, Susan M.
Jaglowski, Samantha
Byrd, John C.
Bannerji, Rajat
Blum, Kristie A.
Fox, Christopher P.
Furman, Richard R.
Hillmen, Peter
Kipps, Thomas J.
Montillo, Marco
Sharman, Jeff
Suzuki, Sam
James, Danelle F.
Chu, Alvina D.
Coutre, Steven E.
JAMA ONCOLOGY, 2018, 4 (05) : 712 - 716
[26] Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis of the German CLL Study Group (GCLLSG)
Al-Sawaf, Othman
Robrecht, Sandra
Bahlo, Jasmin
Fink, Anna-Maria
Cramer, Paula
Maurer, Christian
Bergmann, Manuela
Dreyling, Martin
Lange, Elisabeth
Kneba, Michael
Stilgenbauer, Stephan
Jaeger, Ulrich
Wendtner, Clemens
Fischer, Kirsten
Goede, Valentin
Hallek, Michael
Eichhorst, Barbara
Hopfinger, Georg
Doehner, Hartmut
Kiehl, Michael
LEUKEMIA & LYMPHOMA, 2017, 58 : 62 - 63
[27] Characterization of chronic lymphocytic leukemia (Cll) patients in real-life clinical practice in Helsinki, Finland 2005-015
Lindstrom, Vesa
Mehtala, Juha
Klement, Riho
Leval, Amy
Jarvinen, Tiina
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 358 - 358
[28] Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population
Perkins, JG
Flynn, JM
Howard, RS
Byrd, JC
CANCER, 2002, 94 (07) : 2033 - 2039
[29] Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials
Swarup, Sriman
Quick, Donald P.
Sultan, Anita
D'Cunha, Nicholas
Htut, Thura Win
Hlaing, Pwint Phyu
Sharma, Upama
Adhikari, Nimesh
Aung, Ye
Han, Myat Min
Myat, Yin Mon
Hardwicke, Fred
Tijani, Lukman
Thein, Kyaw Zin
BLOOD, 2019, 134
[30] Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials
Sultan, Anita
Graf, Chandler
Quick, Donald P.
Swarup, Sriman
Kopel, Jonathan
Htut, Thura Win
Adhikari, Nimesh
Han, Myat Min
Myat, Yin Mon
Awasthi, Sanjay
Tijani, Lukman
D'Cunha, Nicholas
Thein, Kyaw Zin
BLOOD, 2019, 134

← 1 2 3 4 5 →